Botulinum toxin inhibits acetylcholine release and therefore could cause mydriasis. We report a case of acute angle-closure glaucoma which occurred shortly after a series of injections of botulinum toxin round the eyelids for blepharospasm. 16 November 1989 TECHNIQUE 0 05 mg of freeze-dried botulinum toxinhaemagglutin complex (0-008 mg neurotoxin) was reconstituted with 1 ml of sterile saline and then diluted in a further 9 ml of saline.3 A 0 5 ml syringe with a 0-36 mmx 12-7 mm needle was used. Four injections of 0-1 ml or 0-15 ml were given subcutaneously round each eye, two immediately above each eyebrow and two a similar distance below the eye.
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Initially she received two 0'15 ml injections above each eye and two 0 -ml injections below each eye, with good relief from blepharospasm and no side effects. Thirteen weeks later blepharospasm had recurred on the right but not on the left. She received two injections of 0-1 ml of toxin above each eye.
Three hours later she developed an ache about her left eye, and within six hours this had become severe and was associated with blurred vision in the left eye, nausea, and vomiting. Despite her severe symptoms she did not seek medical help for her eye condition for a further three days. On examination at the eye casualty department the visual acuity was 6/36 in her right eye 
Discussion
Botulinum neurotoxins act primarily at peripheral cholinergic synapses, where they inhibit the release of acetylcholine.4 They are used clinically for their action on the skeletal muscle neuromuscular junction, causing transient muscle paresis. However, botulinum toxins also inhibit acetylcholine release at sympathetic ganglia and at the preganglionic and postganglionic nerve terminals of the parasympathetic nervous system. People systemically poisoned with botulinum toxins characteristically have mid-dilated fixed pupils due to paralysis of the sympathetic and parasympathetic innervation to the iris.5 Botulinum toxins could therefore cause pupil dilatation by uptake into the parasympathetic neurones at the level of the ciliary ganglion or at the parasympathetic neuromuscular junctions in the sphincter pupillae of the iris. It has been shown in animal studies that botulinum toxin injected intracamerally6 or near the ciliary ganglion7 causes mydriasis. We propose that in this patient's eye, which was predisposed to angle closure, acute glaucoma was precipitated by mydriasis caused by botulinum toxin injection around the eye.
Elston3 reported a series of 243 patients treated with botulinum toxin for involuntary facial movements, mainly blepharospasm. Some developed diplopia, presumably due to diffusion of the toxin from the orbicularis muscle into the oculomotor muscles. Three patients complained of blurred vision, and it is possible that they had Comridan, Nightingale, Mashoudi, Williams ciliary muscle paresis with or without pupil dilatation as a result of botulinum toxin injection.
Scott et al reported a fourfold increase in the incidence of ptosis in patients who, like our patient, had had previous lid surgery. 8 Diffusion of the toxin into adjacent tissues may be greater in this group.
Angle-closure glaucoma did not occur until the second series of injections in our patient. Similarly, cases of mydriatic glaucoma seen in outpatients have often had their pupils dilated uneventfully on more than one occasion before developing angle closure.' (Smith RJH, personal communication.) The symptoms of angle closure in our patient developed only six hours after the injection. Usually the toxin has its maximum effect on the levator on the third postinjection day,'0 when this diagnosis of glaucoma was confirmed. Moreover, the toxin appears to exert an effect more rapidly on the pupils than on skeletal muscle, as in botulism, where blurred vision normally precedes skeletal muscle paralysis. ' This is the first reported case of acute angleclosure glaucoma following a therapeutic injection of botulinum toxin. We recommend gonioscopy to assess the potential for angle closure in all adults prior to treatment with botulinum toxin for blepharospasm, and particularly in those who have had previous eyelid surgery. Patients should be warned of this side effect and advised to report symptoms of early acute glaucoma immediately. Those who are shown to be at risk could have prophylactic YAG laser iridotomies.
